Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C

Antiviral Therapy

Volumn 20, Issue 2, 2015, Pages 185-192

  Ogawa, Eiichi ^a   Furusyo, Norihiro ^a   Shimizu, Motohiro ^a   Ihara, Takeshi ^a   Hayashi, Takeo ^a   Harada, Yuji ^a   Toyoda, Kazuhiro ^a   Murata, Masayuki ^a   Hayashi, Jun ^b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b Kyushu General Internal Medicine Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GENOMIC DNA; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; B CELL LYMPHOMA; BACTERIAL INFECTION; BLOOD TOXICITY; CHRONIC HEPATITIS C; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELASTOGRAPH; ELASTOGRAPHY; FATIGUE; FEMALE; FIB 4 INDEX; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; JAPANESE (PEOPLE); LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METAVIR SCORE; NEUTROPENIA; PHARMACOLOGICAL PARAMETERS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SKIN DISEASE; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; AREA UNDER THE CURVE; BIOPSY; BLOOD; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; THROMBOCYTE COUNT; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; BIOPSY; DRUG THERAPY, COMBINATION; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PLATELET COUNT; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; ROC CURVE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84937553559     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2805     Document Type: Article

References (28)

1. World Health Organization. WHO fact sheet 164 hepatitis C. (Accessed 14 May 2014.) Available from http://www.who.int/mediacentre/factsheets/fs164/en/
2. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833-844.
3. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584-2593.
4. Ogawa E, Furusyo N, Kajiwara E, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013; 58:495-501.
5. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
6. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
7. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
8. Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013; 59:205-212.
9. Serfaty L, Forns X, Goeser T, et al. Insulin resistance and response to telaprevir plus peginterferon a and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012; 61:1473-1480.
10. Furusyo N, Ogawa E, Sudoh M, et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol 2012; 57:1186-1192.
11. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
12. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32-36.
13. de Lédinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-179.
14. Ogawa E, Furusyo N, Toyoda K, et al. Transient elastography for patients with chronic hepatitis B and C virus infection: non-invasive, quantitative assessment of liver fibrosis. Hepatol Res 2007; 37:1002-1010.
15. Ogawa E, Furusyo N, Toyoda K, et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83:127-134.
16. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
17. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20:15-20.
18. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51:828-835.
19. Poynard T, Ingiliz P, Elkrief L, et al. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS ONE 2008; 3:e3857.
20. Ogawa E, Furusyo N, Nakamuta M, et al. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol 2013; 59:667-674.
21. Ogawa E, Furusyo N, Murata M, et al. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays. Antiviral Res 2013; 99:119-124.
22. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19:1321-1324.
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44:837-845.
24. Petta S, Craxì A. How to optimize HCV therapy in genotype 1 patients: predictors of response. Liver Int 2013; 33:23-29.
25. Furusyo N, Ogawa E, Murata M, et al. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. J Antimicrob Chemother 2014; 69:483-490.
26. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a Phase IIb trial. Gastroenterology 2014; 146:430-441.
27. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58:1918-1929.
28. Ogawa E, Furusyo N, Nakamuta M, et al. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment Pharmacol Ther 2013; 38:1076-1085.